News

General Proximity lands $9M Texas grant for 'undruggable' cancer tech

What's the deal? General Proximity, an Austin-based biotech, has received a $9 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)Dealroom has a profile for this one. Try Dealroom →. The money will advance its OmniTAC platform, which targets cancer proteins long considered beyond the reach of conventional drugs.

How it works: OmniTAC uses small molecules to bring two proteins into close proximity, inducing a therapeutic effect. The approach identifies effector proteins that can act on disease-relevant targets, opening a path to drive proteins once labelled "undruggable."

Why now? Many cancer drivers, including tumour suppressors, are lost or inactivated — leaving them untreatable by traditional means. General Proximity was the only company to win a grant in the new technology category this cycle, chosen from 207 applications.

What's the endgame? The grant will fund the move of its lead oncology program into clinical trials. The company is already running multiple preclinical programs from the platform and plans to expand its presence in Texas through partnerships with local clinical sites.

"We are honored to receive this support from CPRIT, which underscores the potential of our OmniTAC platform and offers a glimpse into the future of cancer treatment," said founder and chief executive officer Armand B. Cognetta III.

Context: Founded by the Texas Legislature and approved by voters in 2007, CPRIT has allocated more than $6 billion to cancer research and prevention. At $9 million, this award ranks among the largest health grants in the US, sitting in the top 5% of such rounds on record.

The signal: State-backed grants remain a meaningful funding route for early-stage biotech tackling hard scientific problems. For induced proximity — a field racing to reach undruggable targets — public validation at this scale signals growing confidence that the approach can move from lab to clinic.

Read more: third-news.com

Image credit: Generated with Gemini

More top stories